Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor ends Xopenex copromotion with Abbott

Executive Summary

Sepracor's copromotion deal with Abbott's Ross division for Xopenex (levalbuterol) will end on Dec. 31. Sepracor is moving its sales force in-house as it ramps up for the launch of its insomnia agent Estorra (eszopiclone). Sepracor will expand sales force to approximately 1,250 reps. Estorra has been "approvable" at the agency since Feb. 27 (1"The Pink Sheet" March 8, 2004, p. 34)...
Advertisement

Related Content

Sepracor Estorra Is “Approvable” For Insomnia; Launch Goal Is Mid-Year
Sepracor Estorra Is “Approvable” For Insomnia; Launch Goal Is Mid-Year
Advertisement
UsernamePublicRestriction

Register

PS043640

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel